1 / 3

Dilated Cardiomyopathy (DCM) Market

Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers become stretched, thickened or stiff; this affects the heart's ability to pump blood around the body. <br><br>DelveInsightu2019s u2018Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast u20142030u2019 report delivers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiom

DelveInsight
Download Presentation

Dilated Cardiomyopathy (DCM) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dilated Cardiomyopathy (DCM) Market Insights 2030 Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers become stretched, thickened or stiff; this affects the heart's ability to pump blood around the body. DelveInsight’s ‘Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast —2030’ report delivers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets. Dilated Cardiomyopathy Overview Dilated Cardiomyopathy (DCM) is characterized by left ventricular or biventricular dilation and impaired contraction, which lessens the heart effectiveness at pumping blood that is not explained by abnormal loading conditions like hypertension, valvular heart disease or coronary artery disease. It is a non-ischemic heart muscle disease with structural and functional myocardial abnormalities. The World Health Organization (WHO) defines DCM as a severe cardiac disorder in which structural or functional abnormalities of the heart muscle can lead to substantial morbidity and mortality owing to complications such as heart failure and arrhythmia.

  2. Request https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm- market-insights Dilated Cardiomyopathy Diagnosis The diagnosis of DCM is mainly based on the person's symptoms, the results of a physical examination, and additional tests. Diagnosis usually includes blood test for common viruses which can cause DCM and when doctors suspect infection as an underlying cause. Additionally, electrocardiography (ECG) may detect abnormalities in the electrical activity of the heart. However, these abnormalities are not sufficient evidence for diagnosis usually. Dilated Cardiomyopathy Treatment Currently, the treatment pattern of DCM is mainly dependent on pharmacological therapy, pacing therapy, surgical options, and Corlanor (ivabradine). The pharmacological therapies consist of diuretics, inotropic agents, afterload reducing agents, beta-blockers, anticoagulation medications, anti-arrhythmia medications. Dilated Cardiomyopathy Epidemiology The Dilated Cardiomyopathy epidemiology division provides the insights about historical and current Dilated Cardiomyopathy patient pool and forecasted trend for each seven major countries. Key Findings • The total prevalent cases of Dilated Cardiomyopathy in the 7MM were found to be 2,486,633 in 2017 which is expected to grow during the study period, i.e., 2017–2030. • As per the DelveInsight analysis, the total diagnosed cases of Dilated Cardiomyopathy in the 7MM were 846,615 cases in 2017 which is expected to grow during the study period, i.e., 2017–2030. Dilated Cardiomyopathy Approved Drugs Corlanor (ivabradine): Amgen Dilated Cardiomyopathy Emerging Drugs PF-07265803/ARRY-371797/ARRY-797: Pfizer Ixmyelocel-T: Vericel BC007: Berlin Cures GmbH for a detailed sample copy of the report:

  3. Ifetroban: Cumberland Pharmaceuticals Danicamtiv/MYK-491: MyoKardia CAP-1002: Capricor Therapeutics Click here and get access to a free sample copy of our DCM Market Report. Dilated Cardiomyopathy Market Outlook Besides treating any recognizable and reversible underlying causes, the management and treatment of DCM are in concordance with the standard heart failure guidelines. Currently, the treatment pattern of DCM is mainly dependent on pharmacological therapy, pacing therapy, surgical options, and Corlanor (ivabradine). Key Findings According to DelveInsight’s estimates, the total Dilated Cardiomyopathy therapeutic market in seven major markets was found to be USD 244 million in 2017 which is expected to increase during the study period 2017–30. Related Reports Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2030 Dilated Cardiomyopathy - Pipeline Insights, 2021 Visit our Insightful Press Release @https://icrowdnewswire.com/2021/05/03/rich- insights-into-end-stage-renal-disease-esrd-market-epidemiology-segmentation-pipeline- therapies-and-major-key-players-involved/ About DelveInsight: DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences providing comprehensive end-to-end solutions to improve performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

More Related